FAHA

Noted Health leader Richard Levin Joins FINN Partners as Chief Health Affairs Counselor

Retrieved on: 
Martedì, Maggio 7, 2024
Genomics, FAHA, Patient, Health Affairs, Education, Heart, Dean, MD, NYU Langone Health, Agency, Emeritus, Artificial intelligence, Humanism, NYU, Human, FACC, Science, GDP, Health policy, Health, Empathy, Rich, Faculty, Government, FACP, American Heart Association, McGill University, Global health, Nursing

NEW YORK, May 7, 2024 /PRNewswire/ -- FINN Partners today announced that noted cardiologist and national health policy and affairs voice Richard I. Levin, MD, FACP, FACC, FAHA, joins the Agency as its Chief Health Affairs Counselor.  Dr. Levin was most recently President and CEO of The Arnold P. Gold Foundation and is an Emeritus Professor of Medicine and Cardiology at McGill and New York Universities. In this newly created role at FINN, he reports to Gil Bashe, chair, global health and purpose at FINN.

Key Points: 
  • NEW YORK, May 7, 2024 /PRNewswire/ -- FINN Partners today announced that noted cardiologist and national health policy and affairs voice Richard I. Levin, MD, FACP, FACC, FAHA, joins the Agency as its Chief Health Affairs Counselor.
  • In this newly created role at FINN, he reports to Gil Bashe, chair, global health and purpose at FINN.
  • "One of America's famous health leaders refers to the modern academic health center as 'the most complex invention of humanity.'
  • "I am thrilled to have the breadth of his scientific and clinical experience and health policy expertise connected to FINN," she added.

People Think They Know More about Stroke Warning Signs than They Actually Do According to a New MedStar Health Survey

Retrieved on: 
Mercoledì, Maggio 1, 2024
MedStar Health, MedStar Washington Hospital Center, Cancer, FAHA, Stroke, Hospital, Certification, Risk, MedSTAR, Death, Research, MedStar Georgetown University Hospital, Life, Joint Commission, Patient, MPH, Multimedia, CSCS

COLUMBIA, Md., May 1, 2024 /PRNewswire/ -- A survey conducted by MedStar Health found people could be overly confident about their ability to recognize the serious warning signs of someone having a stroke. The national survey of 1000 people found 64% of respondents said they were "confident" about their knowledge of stroke symptoms, but just 23% could name the signs that make up the widely known acronym BEFAST which outlines sudden changes that can be signs of stroke:

Key Points: 
  • Stroke was the third leading health condition survey respondents said they're concerned about personally after heart disease and cancer.
  • "A crucial step in providing equitable health care is ensuring that we're reaching communities with accessible and culturally tailored messaging.
  • RÁPIDO aims to break down the language barrier to initiating acute stroke care in Spanish speaking communities."
  • MedStar Washington Hospital Center, MedStar Georgetown University Hospital, and MedStar Franklin Square Medical Center all offer Comprehensive Stroke Centers (CSCs) accredited by The Joint Commission .

5 Ways Heart Health Care Can Improve

Retrieved on: 
Lunedì, Aprile 29, 2024
The Harris Poll, Education, Brain, Public, Cancer, Food, Disorder, FAHA, Stroke, Pneumonia, Housing, Prevalence, CVD, Risk, Health, Infection, Heart, Radiology, Death, Research, Artificial intelligence, Life, Stanford School, Disease, Moyamoya disease, Physician, Cardiovascular disease, Diphtheria, Roflumilast, Tuberculosis, Overalls, American Heart Association, Heart failure, Pharmaceutical industry

"Finding that most people do not know the significant impact of heart disease is discouraging and even a bit frightening."

Key Points: 
  • "Finding that most people do not know the significant impact of heart disease is discouraging and even a bit frightening."
  • Non-traditional approaches to health care are needed to address the social and structural determinants of health by moving evidence-based approaches rapidly into communities to address food insecurity, transportation problems, education, housing, access to care, chronic psychosocial stress and other social needs.
  • The interconnectedness of organ systems, mechanisms of disease and stages of life are critical to understanding the role cardiovascular health plays in overall health.
  • As we apply these same clinical and epidemiological methods to the someday hopeful eradication of heart disease and stroke, the American Heart Association is making great progress.

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Retrieved on: 
Domenica, Aprile 7, 2024
Uric acid, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, Atherosclerosis, FAHA, Cleveland Clinic, Bempedoic acid, Ezetimibe, Therapy, Anemia, Pain, MACE, Sinusitis, ACC, FOMA, FNLA, FACC, Obesity, Cardiovascular disease, Esperion Therapeutics, Abdominal pain, Risk, Gout, Spasm, Woman, American College, Body mass index, ESPR, Back pain, Outcome, ATP, Safety, Fatigue, Arthralgia, ANN, Angioedema, Kidney, Journal, Constipation, University, Adverse event, Pregnancy, CLEAR, Rash, MPH, Rupture, FDA, Molina Healthcare, JACC, Hypersensitivity, Health, Circulatory system, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Dietary supplement

ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced the presentation of results from three pre-specified subgroups from CLEAR Outcomes at the 2024 American College of Cardiology’s Annual Scientific Sessions (ACC.24): women, Hispanic/Latinx, and patients with obesity. These results align with the American College of Cardiology’s robust diversity, equity and inclusion programs to drive cultural change across the profession and ensure that the cardiovascular care team is as diverse as the patients they care for and that all patients are represented in cardiovascular research. The data also reinforce the mission of the ACC: transforming cardiovascular care for all.

Key Points: 
  • “Bempedoic acid is the only FDA approved non-statin LDL lowering therapy to demonstrate reductions in MACE in both primary prevention and secondary prevention patient populations.
  • The Hispanic population is the largest ethnic minority in the U.S., yet is a population historically underrepresented in clinical trials.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

Retrieved on: 
Martedì, Marzo 12, 2024
Abstract, Chlorine, Survival, SOT, University, Doctor of Philosophy, MD, Code, FAHA, Society, Translation, Safety, Tokyo Stock Exchange, ALI, Edema

In this study, single-dose and multi-dose treatments were evaluated.

Key Points: 
  • In this study, single-dose and multi-dose treatments were evaluated.
  • The primary endpoint was the mean change in the pulmonary function measure PaO2/FiO2, which is the ratio of arterial oxygen partial pressure to fractional inspired oxygen.
  • Additional endpoints included survival, lung mechanics, lung injury, and edema formation evaluated by chest x-ray.
  • Cl2 gas concentration of 210 ppm x 30 min was expected to result in a 20 - 30% mortality rate (Fukuda 2015).

Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline

Retrieved on: 
Mercoledì, Marzo 27, 2024
Element, Myocardial infarction, FACC, Interest, AMI, Growth, Lupus, Cardiology, SPA, Patient, Columbia University, NYU, Faculty, FAHA, MBA, FESC, Heart failure, MPH, Safety, OPUS, FDA, Autoimmune disease, Food, Hospital, Pharmaceutical industry

The focus of the event will be a discussion of its collaboration with Idorsia, Phase 3 assets selatogrel and cenerimod and key elements of the Company's pipeline.

Key Points: 
  • The focus of the event will be a discussion of its collaboration with Idorsia, Phase 3 assets selatogrel and cenerimod and key elements of the Company's pipeline.
  • The collaboration with Idorsia is a great example of Viatris' strategy in action—adding two late-stage potential blockbuster assets, selatogrel and cenerimod—and connecting Idorsia's highly productive drug development team and innovation engine with Viatris' existing infrastructure and experience.
  • The Company will review key elements of the collaboration including how Viatris can make a difference in the delivery of these assets.
  • An archived version also will be available following the live event and can be accessed at the same location for a limited time.

The American Diabetes Association Announces the 2024 National Scientific and Health Care Achievement Award Winners

Retrieved on: 
Mercoledì, Marzo 6, 2024
Reward, Bachelor of Science, Nursing, Royal College of Pathologists, Doctor of Philosophy, Pregnancy, University, FRCP, CUPS, Social media, American Diabetes Association, Doctor of Science, MB, FESC, Lois Jovanovic, FACP, FACE, FACC, MRCP, Book, Physician, Female, Doctor of Pharmacy, Life, Learning, Prognosis, Prediabetes, Insulin resistance, Lond, Research, FAHA, Interest, Patient, Causality, Public

ARLINGTON, Va., March 6, 2024 /PRNewswire/ -- The American Diabetes Association® is pleased to announce this year's National Scientific and Health Care Achievement Award recipients.

Key Points: 
  • ARLINGTON, Va., March 6, 2024 /PRNewswire/ -- The American Diabetes Association® is pleased to announce this year's National Scientific and Health Care Achievement Award recipients.
  • The awards honor academics, health care providers, and educators who have contributed to substantial advances in diabetes care and research.
  • ), FMedSci is the recipient of the 2024 Banting Medal for Scientific Achievement, which recognizes significant long-term contributions to the understanding, treatment, or prevention of diabetes.
  • Parker, PhD is the recipient of the 2024 Outstanding Scientific Achievement Award, which recognizes research in diabetes that demonstrates particular independence of thought and originality.

Kelvin Health joins Innovators' Network at American Heart Association Center for Health Technology & Innovation

Retrieved on: 
Mercoledì, Febbraio 28, 2024
Cornell University, Innovation, American Heart Association, FAHA, Cardiovascular disease, Weill Cornell Medicine, American Heart, Network, Science

SOFIA, Bulgaria, Feb. 28, 2024 /PRNewswire/ -- Kelvin Health, diagnostic solution aiming to advance the standard of vascular care by applying modern AI to mobile thermography imaging, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

Key Points: 
  • SOFIA, Bulgaria, Feb. 28, 2024 /PRNewswire/ -- Kelvin Health, diagnostic solution aiming to advance the standard of vascular care by applying modern AI to mobile thermography imaging, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network.
  • The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.
  • The Innovators' Network is a health care technology consortium that connects entrepreneurs, providers, researchers, and payers.
  • Innovators' Network members also have access to the Association's digital guidelines, recommendations, and best-in-class science as they develop digital healthcare technologies.

MelliCell Announces Dr. Fatima Cody Stanford as New Advisory Board Member

Retrieved on: 
Martedì, Febbraio 27, 2024
Diabetes, FAAP, Obesity, FAHA, Hospital, MPA, MBA, DSM-IV codes, MGH, FACP, Human, CNN, PBS, Associate, HMS, Pediatrics, Massachusetts General Hospital, Harvard Medical School, Adipose tissue, Research, Public

This strategic move aligns with MelliCell's mission to revolutionize the treatment and understanding of metabolic diseases through advanced fat cell research.

Key Points: 
  • This strategic move aligns with MelliCell's mission to revolutionize the treatment and understanding of metabolic diseases through advanced fat cell research.
  • Dr. Stanford brings to MelliCell a rich legacy of expertise in obesity medicine as an Associate Professor of Medicine and Pediatrics at Massachusetts General Hospital (MGH) / Harvard Medical School (HMS).
  • As MelliCell prepares for its upcoming funding round, the addition of Dr. Stanford to the advisory board marks a pivotal moment in the company's trajectory towards establishing new standards in metabolic disease treatment.
  • "Joining MelliCell's dynamic team is an exciting opportunity to advance the fight against obesity through our focused research on adipose tissue," expressed Dr. Stanford.

PUER Joins Campden Wealth As a Corporate Partner to Provide Multigenerational Health Resources

Retrieved on: 
Mercoledì, Febbraio 21, 2024
Biotechnology, Education, Cholesterol, Physician, Molecular medicine, FAHA, Drug development, System, Health, Therapy, UHNW, Genome, FACC, Genomics, Trial of the century, Management

ATLANTA, Feb. 21, 2024 /PRNewswire/ -- PUER, a bespoke scientific multigenerational concierge program, announced today that it is joining Campden Wealth, the preeminent peer networking group for families and ultra-high net worth individuals, as a corporate partner to offer cutting-edge health and wellness resources to Campden Wealth's members.

Key Points: 
  • ATLANTA, Feb. 21, 2024 /PRNewswire/ -- PUER, a bespoke scientific multigenerational concierge program, announced today that it is joining Campden Wealth, the preeminent peer networking group for families and ultra-high net worth individuals, as a corporate partner to offer cutting-edge health and wellness resources to Campden Wealth's members.
  • PUER is joining the Campden Wealth community as one of Campden Wealth's select corporate partners for 2024.
  • PUER offers a high-touch, high-science, multigenerational concierge program with the most comprehensive health planning for families.
  • A centennial time horizon aims to complement multigenerational family education and resources facilitated by Campden Wealth.